Open AccessP1063: EFFICACY AND SAFETY OF PARSACLISIB‐RUXOLITINIB COMBINATION THERAPY IN MYELOFIBROSIS PATIENTS WITH LOW VS HIGHER BASELINE PLATELET COUNT: A SUBGROUP ANALYSIS OF DATA FROM A PHASE 2 STUDY
Author(s) -
Yacoub A.,
Borate U.,
Rampal R.,
Ali H.,
Wang E.,
Gerds A.,
Hobbs G.,
Kremyanskaya M.,
Winton E.,
O'Connell C.,
Goel S.,
Oh S.,
Schiller G.,
Assad A.,
EricksonViitanen S.,
Zhou F.,
Daver N.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847120.16268.0f
Subject(s) - ruxolitinib , myelofibrosis , medicine , subgroup analysis , phases of clinical research , clinical trial , gastroenterology , surgery , bone marrow , confidence interval